Alnylam Pharmaceuticals
ALNY
#583
Rank
A$59.64 B
Marketcap
A$451.46
Share price
-2.49%
Change (1 day)
3.10%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Cash on Hand

Cash on Hand as of September 2025 : A$3.84 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company has A$3.84 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

Alnylam Pharmaceuticals - Cash on Hand chart (from 2003 to 2025)

Cash on Hand by year

Year Cash on Hand Change
2024-12-31A$4.33 B20.99%
2023-12-31A$3.58 B11.13%
2022-12-31A$3.22 B-4.1%
2021-12-31A$3.35 B37.82%
2020-12-31A$2.43 B11.1%
2019-12-31A$2.19 B42.57%
2018-12-31A$1.53 B-28.93%
2017-12-31A$2.16 B149.04%
2016-12-31A$0.86 B-41.37%
2015-12-31A$1.48 B74.24%
2014-12-31A$0.85 B208.83%
2013-12-31A$0.27 B133.24%
2012-12-31A$0.11 B-17.23%
2011-12-31A$0.14 B-37.79%
2010-12-31A$0.22 B-26.73%
2009-12-31A$0.31 B-48.65%
2008-12-31A$0.61 B36.77%
2007-12-31A$0.44 B61.83%
2006-12-31A$0.27 B152.07%
2005-12-31A$0.10 B83.75%
2004-12-31A$59.5 M90.7%
2003-12-31A$31.2 M13.59%
2002-12-31A$27.47 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
Novartis
NVS
A$16.27 B 323.29%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$14.74 B 283.61%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$12.14 B 215.83%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A$1.20 B-68.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
A$92.22 M-97.60%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
A$0.58 B-84.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$5.01 B 30.51%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
A$1.29 B-66.36%๐Ÿ‡บ๐Ÿ‡ธ USA